Alembic Pharmaceuticals Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| APLLTD.NS | ALKEM.NS | AUROPHARMA.NS | AKUMS.NS | GRANULES.BO | IPCALAB.BO | |
|---|---|---|---|---|---|---|
| Market cap | 154.71B | 599.62B | 908.41B | 106.41B | 194.90B | 486.30B |
| P/E (TTM) | 22.3 | 27.8 | 24.7 | 36.5 | 35.7 | 37.1 |
| Forward P/E | 16.1 | 22.4 | 16.9 | 20.4 | 26.8 | 27.2 |
| Price/book | 2.7 | 4.3 | 2.4 | 3.2 | 4.9 | 6.0 |
| Dividend yield | 1.52% | 0.40% | — | 0.14% | 0.26% | 0.33% |
| 1-year change | −15.27% | −9.58% | +47.52% | +50.86% | +0.63% | +42.82% |
| Today | −0.42% | +0.22% | −2.63% | −2.05% | −0.43% | +5.60% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All APLLTD.NS news ›Alembic Pharmaceuticals Ltd receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%.
Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP,…
Alembic Pharmaceuticals: Gets USFDA Approval for Otic Suspension
InvestyWise delivers real-time Indian stock market news, corporate filings, regulatory disclosures, and financial analysis. Track NSE and BSE-listed companies with AI-powered insights for smarter investment decisions. Alembic…
From articles in the 4Search news index.